Work

Exposure-response analysis for avutometinib in combination with defactinib in low-grade serous ovarian cancer

Year: 2026

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2026.01.248

Authors: Yaofeng Cheng, Sarath Nagothu, Dinesh Vippala, Susana Banerjee, Rachel Grisham, David O'Malley, Els Van Nieuwenhuysen, Udai Banerji, D. Ross Camidge, Joshua Reuss, Azita Razzaghi, Paraneedharan Ramachandran, John Hayslip, Jonathan Pachter, Stephanie Lustgarten

Institutions: Verastem (United States), Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Lyon 1 Université, Centre Léon Bérard, KU Leuven, Royal Marsden Hospital, University of Colorado Anschutz, University of Colorado Denver, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7155367125

FWCI:

Cites:

Cited by:

Related to: 10